Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.

Acknowledgment of Support

This activity is supported by an educational grant from Bayer Healthcare.

Advances in™ Chronic Kidney Disease: Keys to Early Diagnosis and Successful Intervention

Release Date: November 24, 2020
Expiration Date: November 24, 2021

Activity Overview

A recent study by Bakris et al found that roughly 50% of patients with chronic kidney disease (CKD) had not been diagnosed. In the ADD-CKD trial, a nationwide study of primary care physicians that examined screening practices in patients with diabetic kidney disease (DKD), 50% of patients did not receive screening, while almost 40% were screened but did not receive a diagnosis. In addition to deficiencies in recognizing CKD, effective treatment for DKD is a key unmet need. Although advances in diabetes care have substantially reduced the incidence of many diabetes complications, efforts to reduce progression to end stage renal disease (ESRD) have lagged behind. In therapeutics, many novel advancements are being made in the treatment of DKD. Studies are being conducted using agents ranging from allopurinol to endothelin receptor antagonists. One investigational class of non-glucose lowering agents, nonsteroidal mineralocorticoid receptor antagonists, has resulted in improved renal outcomes among patients who present with diabetic nephropathy that remains uncontrolled with current glucose-lowering therapies.

In this program, George Bakris, MD, MA, outlines his strategies for diagnosing and monitoring CKD in patients with type 2 diabetes mellitus (T2D), with a focus on slowing the progression of kidney disease. He reviews recent study results regarding existing and emerging therapies, and previews clinical trials that he anticipates will provide more answers regarding effective therapies for patients with CKD and novel renoprotective strategies.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Bayer Healthcare.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This online educational activity is directed toward primary care physicians, nephrologists, endocrinologists, physician assistants, and nurses specializing in kidney disorders.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Describe recommended diagnostic practices for CKD in patients with T2DM
  • Identify CKD as a unique disease with high risk of cardiovascular and renal comorbidities
  • Evaluate the efficacy and safety of nonsteroidal mineralocorticoid receptor antagonists and other therapies under investigation for treatment of patients with CKD
  • Recognize the complex pathophysiology of CKD and emerging approaches to intervene in disease progression

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


George Bakris, MD, MA
George Bakris, MD, MA
Professor of Medicine
Director, Comprehensive Hypertension Center
University of Chicago Medicine
Chicago, IL

Disclosures: Grant/Research Support: Novo Nordisk, Vascular Dynamics; Consultant: Merck, Relypsa, Vifor Pharma, AstraZeneca, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Bayer.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By